Results 11 to 20 of about 10,300,849 (340)

Synthesized Anti-HER2 Trastuzumab-MCC-DM1 Conjugate: An Evaluation of Efficacy and Cytotoxicity [PDF]

Iranian Journal of Immunology, 2023
Background: Trastuzumab is a humanized monoclonal antibody that targets site-specifically human epidermal growth factor-2 receptor (HER2) cell surface antigen overexpressed in approximately 20% of human breast carcinomas. Despite its positive therapeutic
Soodabeh Shafiee, Roya Mirzaei, Malihe Salehi, Neda Jalili, Amir Taheri, Leila Farahmand   +5 more
doaj   +1 more source

Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk

Cancer Cell International, 2022
As an intelligent disease, tumors apply several pathways to evade the immune system. It can use alternative routes to bypass intracellular signaling pathways, such as nuclear factor-κB (NF-κB), Wnt, and mitogen-activated protein (MAP)/phosphoinositide 3 ...
Khadijeh Barzaman, Rana Vafaei, Mitra Samadi, Mohammad Hossein Kazemi, Aysooda Hosseinzadeh, Parnaz Merikhian, Shima Moradi-Kalbolandi, Mohammad Reza Eisavand, Houra Dinvari, Leila Farahmand   +9 more
doaj   +1 more source

Plasmin activity promotes amyloid deposition in a transgenic model of human transthyretin amyloidosis

Nature Communications, 2021
ATTR amyloidosis causes heart failure through the accumulation of misfolded transthyretin in cardiac muscle. Here the authors report a mouse model of ATTR amyloidosis and demonstrate the involvement of protease activity in ATTR amyloid deposition.
Ivana Slamova, Rozita Adib, Stephan Ellmerich, Michal R. Golos, Janet A. Gilbertson, Nicola Botcher, Diana Canetti, Graham W. Taylor, Nigel Rendell, Glenys A. Tennent, Guglielmo Verona, Riccardo Porcari, P. Patrizia Mangione, Julian D. Gillmore, Mark B. Pepys, Vittorio Bellotti, Philip N. Hawkins, Raya Al-Shawi, J. Paul Simons   +18 more
doaj   +1 more source

MUC1 is a potential target to overcome trastuzumab resistance in breast cancer therapy

Cancer Cell International, 2022
Although resistance is its major obstacle in cancer therapy, trastuzumab is the most successful agent in treating epidermal growth factor receptor 2 positive (HER2 +) breast cancer (BC).
Aysooda Hosseinzadeh, Parnaz Merikhian, Nazanin Naseri, Mohammad Reza Eisavand, Leila Farahmand   +4 more
doaj   +1 more source

Engineered hypoxia-responding Escherichia coli carrying cardiac peptide genes, suppresses tumor growth, angiogenesis and metastasis in vivo

Journal of Biological Engineering, 2021
Development of engineered non-pathogenic bacteria, capable of expressing anti-cancer proteins under tumor-specific conditions, is an ideal approach for selectively eradicating proliferating cancer cells.
Mitra Samadi, Keivan Majidzadeh-A, Malihe Salehi, Neda Jalili, Zeinab Noorinejad, Marjan Mosayebzadeh, Ahad Muhammadnejad, Azadeh Sharif khatibi, Shima Moradi-Kalbolandi, Leila Farahmand   +9 more
doaj   +1 more source

Design and characterization of a protein fold switching network

Nature Communications, 2023
In this work the authors investigate the structure-sequence dependance. The ability to design and characterize proteins at interfaces between three common folds suggests that fold switching is an intrinsic feature of protein folding language and likely ...
Biao Ruan, Yanan He, Yingwei Chen, Eun Jung Choi, Yihong Chen, Dana Motabar, Tsega Solomon, Richard Simmerman, Thomas Kauffman, D. Travis Gallagher, John Orban, Philip N. Bryan   +11 more
doaj   +1 more source

Comparison of mucin-1 in human breast cancer and canine mammary gland tumor: a review study

Cancer Cell International, 2022
Mucin-1 (MUC-1) is a transmembrane glycoprotein, which bears many similarities between dogs and humans. Since the existence of animal models is essential to understand the significant factors involved in breast cancer mechanisms, canine mammary tumors ...
Rana Vafaei, Mitra Samadi, Aysooda Hosseinzadeh, Khadijeh Barzaman, MohammadReza Esmailinejad, Zohreh Khaki, Leila Farahmand   +6 more
doaj   +1 more source

Combined docking and machine learning identify key molecular determinants of ligand pharmacological activity on β2 adrenoceptor

Pharmacology Research & Perspectives, 2022
G protein‐coupled receptors (GPCRs) are valuable therapeutic targets for many diseases. A central question of GPCR drug discovery is to understand what determines the agonism or antagonism of ligands that bind them.
Mireia Jiménez‐Rosés, Bradley Angus Morgan, Maria Jimenez Sigstad, Thuy Duong Zoe Tran, Rohini Srivastava, Asuman Bunsuz, Leire Borrega‐Román, Pattarin Hompluem, Sean A. Cullum, Clare R. Harwood, Eline J. Koers, David A. Sykes, Iain B. Styles, Dmitry B. Veprintsev   +13 more
doaj   +1 more source

DETERMINATION OF SERUM PROTEINS BY MEANS OF THE BIURET REACTION

Journal of Biological Chemistry, 1949
Allan G. Gornall, Charles J. Bardawill, Maxima M. David   +2 more
openalex   +2 more sources

A prospective study of nutritional status in immunoglobulin light chain amyloidosis

Haematologica, 2013
Weight loss is common in systemic immunoglobulin light chain amyloidosis but there are limited data on the impact of nutritional status on outcome.
Prayman T. Sattianayagam, Thirusha Lane, Zoe Fox, Aviva Petrie, Simon D.J. Gibbs, Jennifer H. Pinney, Signe S. Risom, Dorota M. Rowczenio, Ashutosh D. Wechalekar, Helen J. Lachmann, Janet A. Gilbertson, Philip N. Hawkins, Julian D. Gillmore   +12 more
doaj   +1 more source